BR100 Decreased By (-0.85%)
BR30 Decreased By (-1.05%)
KSE100 Decreased By (-2.53%)
KSE30 Decreased By (-2.55%)
BECO 5.48 Decreased By ▼ -0.12 (-2.14%)
BML 63.63 Increased By ▲ 2.68 (4.4%)
BOP 36.76 Decreased By ▼ -0.61 (-1.63%)
CNERGY 8.68 Increased By ▲ 0.19 (2.24%)
DCL 11.65 Decreased By ▼ -0.10 (-0.85%)
FCCL 57.89 Increased By ▲ 0.14 (0.24%)
FCSC 5.03 Decreased By ▼ -0.01 (-0.2%)
FFL 17.83 Decreased By ▼ -0.06 (-0.34%)
FNEL 1.23 Decreased By ▼ -0.01 (-0.81%)
HUMNL 11.20 No Change ▼ 0.00 (0%)
KEL 8.16 Increased By ▲ 0.05 (0.62%)
KOSM 6.30 Decreased By ▼ -0.07 (-1.1%)
MLCF 105.08 Decreased By ▼ -1.98 (-1.85%)
NBP 214.57 Decreased By ▼ -3.74 (-1.71%)
PACE 11.35 Increased By ▲ 0.18 (1.61%)
PAEL 46.05 Decreased By ▼ -0.97 (-2.06%)
PIAHCLA 29.85 Decreased By ▼ -0.81 (-2.64%)
PIBTL 18.44 Decreased By ▼ -0.18 (-0.97%)
PPL 244.05 Decreased By ▼ -2.77 (-1.12%)
PRL 38.73 Increased By ▲ 1.48 (3.97%)
PTC 70.80 Decreased By ▼ -0.80 (-1.12%)
SEARL 97.50 Decreased By ▼ -1.66 (-1.67%)
SSGC 31.51 Decreased By ▼ -0.43 (-1.35%)
TELE 9.10 Decreased By ▼ -0.08 (-0.87%)
THCCL 74.32 Increased By ▲ 0.12 (0.16%)
TPLP 12.97 Decreased By ▼ -0.35 (-2.63%)
TREET 25.55 Decreased By ▼ -0.31 (-1.2%)
TRG 66.83 Decreased By ▼ -0.67 (-0.99%)
WAVES 11.30 Decreased By ▼ -0.21 (-1.82%)
WTL 1.29 Increased By ▲ 0.02 (1.57%)

Pakistan produces Chinese CanSinoBio COVID vaccine, brands it PakVac

  • Pakistan signed a deal with CansinoBio late March to import a concentrate of the vaccine in bulk to process and package the vaccine locally.
  • This is a co-production along with CanSino in Pakistan.
  • The plant will start producing 3 million doses a month starting July.
Published Updated
By

ISLAMABAD: Pakistan has started producing the single dose Chinese CanSinoBio COVID-19 vaccine to be able to deliver 3 million doses a month, health officials said.

Branded PakVac, an initial batch of 118,000 doses of the vaccine is ready to be delivered to the government on Friday, the National Institute of Health (NIH) said two days after the inauguration of the production plant in Islamabad.

Pakistan signed a deal with CansinoBio late March to import a concentrate of the vaccine in bulk to process and package the vaccine locally.

"This is a co-production along with CanSino in Pakistan," professor Aamer Ikram, the NIH's executive director, told Reuters.

Ikram said the Chinese firm was supplying a vaccine concentrate which the plant then formulated, processed and packaged. CanSinBio had transferred some of its production technology to Pakistan and is supervising operations, he said.

Quality control was being carried out by Pakistan. "We've acquired technology and expertise to ensure quality control," he said.

The plant will start producing 3 million doses a month starting July, he said.

SELF RELIANCE

At the plant's inauguration on Tuesday, Health Minister Faisal Sultan described the local production a "milestone in the journey to achieve to self-reliance".

Both him and Ikram said the transfer of technology could help Pakistan to eventually manufacture the vaccine.

To be more cost effective, 10 doses of PakVac will be filled into one vial.

According to the officials PakVac will save around 25% on vaccine cost, which according to government figures amounts to $250 million so far.

Pakistan, which has a population of 220 million people, faced initial vaccination hesitancy and a shortage of vaccine supplies, but last week started mass vaccination for all adults.

It has so far relied heavily on its ally China in vaccine procurement and of the six vaccines approved for use in Pakistan, three - Sinopharm, SinoVac and CanSinoBio - are from China.

The government says it has procured over 18 million vaccine doses via purchases or donations from China and allocations from the World Health Organisation and the GAVI Vaccine Alliance.

The inoculation programme has administered 8.5 million doses of coronavirus vaccines so far, according to official figures. Pakistan reported more than 928,000 coronavirus infections and 21,105 deaths, with 1,893 cases and 83 fatalities on Friday.

Pakistan's biotech and pharmaceutical industry is underdeveloped and the country produces few vaccines.

"Our cooperation not only effectively contributes to Pakistan's efforts in fighting against the COVID-19 ... it reduces its dependence of the vaccine import," said Chinese ambassador to Pakistan Nong Rong said at the plant's inauguration.

Comments

Comments are closed for this article.